



ALK  
Investor Relations Department  
BÃge Alle 6-8  
Horsholm DK-2970  
Denmark

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### OMX: ALKB

Last Trade:	744.00
Trade Time:	4:59 PM ET Dec 8, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	681.00 - 1133.00
Volume	3,993,200

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

## Company releases [\[ View all \]](#)

*Dec 7, 2017*

[Report on transactions with ALK-Abell A/S B-shares and associated securities by managerial staff](#)

*Dec 7, 2017*

[Indberetning af ledelsens transaktioner med ALK-Abell A/S' B-aktier og tilknyttede vrdipapirer](#)

*Dec 7, 2017*

[PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELL A/S](#)

*Dec 6, 2017*

[ALK-ABELL A/S TO ISSUE UP TO 92,076 AA SHARES AND UP TO 920,760 B SHARES IN A PRIVATE PLACEMENT](#)

*Dec 4, 2017*

[ALK launches ambitious, transformational growth strategy](#)